| 0 (0%) | 09-27 09:27 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.91 | 1-year : | 18.68 |
| Resists | First : | 14.48 | Second : | 16 |
| Pivot price | 12.66  |
|||
| Supports | First : | 12.02 | Second : | 10 |
| MAs | MA(5) : | 12.77 |
MA(20) : | 12.96 |
| MA(100) : | 16 |
MA(250) : | 22.08 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 25.1 |
D(3) : | 31.3 |
| RSI | RSI(14): 41.8  |
|||
| 52-week | High : | 63 | Low : | 10.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CBIO ] has closed above bottom band by 29.0%. Bollinger Bands are 75.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 12.62 - 12.68 | 12.68 - 12.74 |
| Low: | 12.03 - 12.1 | 12.1 - 12.16 |
| Close: | 12.32 - 12.43 | 12.43 - 12.53 |
Wed, 17 Sep 2025
With 36% stake, Crescent Biopharma, Inc. (NASDAQ:CBIO) seems to have captured institutional investors' interest - Yahoo Finance
Sat, 13 Sep 2025
LifeSci Capital Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $22 - 富途牛牛
Thu, 28 Aug 2025
Cancer Drug Developer Crescent Biopharma to Present at Major September Healthcare Conferences - Stock Titan
Mon, 25 Aug 2025
This Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Mon, 18 Aug 2025
Crescent Biopharma: Chasing The Summit Hype - Seeking Alpha
Thu, 31 Jul 2025
Crescent Biopharma Raises $200M to Accelerate Next-Gen Cancer Therapies Development Following Strategic Merger - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 14 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 6.6 (%) |
| Held by Institutions | 77.3 (%) |
| Shares Short | 141 (K) |
| Shares Short P.Month | 90 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 1.74 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.89 |
| Dividend | 24 |
| Forward Dividend | 0 |
| Dividend Yield | 193% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|